Pulmonary Arterial Hypertension
4 competing products in clinical development for Pulmonary Arterial Hypertension.
Pipeline by Phase
Pre-clinical1
Phase 23
All Products (4)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Satralizumab (Genetical Recombination) | Chugai Pharmaceutical | Phase 2 | Active | 39 |
| CS1 Administration | Cereno Scientific | Phase 2 | Completed | 29 |
| Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Keros Therapeutics | Phase 2 | Completed | 25 |
| CS1 | Cereno Scientific | Pre-clinical | Active | 24 |